179
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacotherapy for erectile dysfunction in diabetic males

Pages 1345-1356 | Received 22 Apr 2018, Accepted 24 Jul 2018, Published online: 14 Aug 2018

References

  • El-Sakka AI, Tayeb KA. Erectile dysfunction risk factors in non-insulin dependent diabetic Saudi patients. J Urol. 2003;169:1043–1047.
  • Fedele D, Bortolotti A, Coscelli C, et al. Erectile dysfunction in type 1and type 2 diabetics in Italy. On behalf of gruppo Italiano studio deficit erettilenei diabetici. Int J Epidemiol. 2000;29:524.
  • El-Sakka AI, Lin CS, Chui RM, Dahiya R and Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res. 1999;11:123.
  • Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151:54.
  • Fedele D, Bortolotti A, Coscelli C, et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. Int J Epidemiol. 2000;29:524.
  • Greenstein A, Chen J, Miller H, et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res. 1997;9:123–126.
  • Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;26:181–184.
  • Shabsigh R, Fishman IJ, Schum C, et al. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology. 1991;38:227–231.
  • Zorgniotti AW. Potency problems in cardiac patients and arteriopaths. In: Kirby RS, Carson C, Webster GD, editors. Impotence diagnosis and management of male erectile dysfunction. Oxford, UK: Butterworth Heinemann Ltd; 1991. p. 232.
  • Statistical abstract of the United States 1992. 112th. Washington, D.C: United States Bureau of the Census; 1992. p. 19.
  • Harman SM, Metter EJ, Tobin JD, et al. Baltimore longitudinal study of aging: longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metabolism. 2001;86:724–731.
  • McKinlay JB, Longcope C, Gray A. The questionable physiologic and epidemiologic basis for a male climacteric syndrome: preliminary results from the Massachusetts male aging study. Maturitas. 1989;11:103–115.
  • Travison TG, Shabsigh R, Araujo AB, et al. The natural progression and remission of erectile dysfunction: results from the Massachusetts male aging study. J Urol. 2007;177:241–246.
  • Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–2984.
  • Jackson G, Rosen RC, Kloner RA, et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3:28–36.
  • Biebel MG, Burnett AL. Sadeghi-Nejad H male sexual function and smoking. Sex Med Rev. 2016 Oct;4(4):366–375.
  • Bala A, Nguyen HMT. Hellstrom WJG Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018 Jan;6(1):29–34.
  • Patel DP, Craig JR, Myers JB, et al. Serum biomarkers of erectile dysfunction in diabetes mellitus: a systematic review of current literature. Sex Med Rev. 2017;5:339–348.
  • Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130–171.
  • Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(29):M–31M.
  • Sadovsky R, Brock GB, Gutkin SW, et al. Toward a new “EPOCH”: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract. 2009;63:1214–1230.
  • Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002;60(2 Suppl 2):12–27.
  • Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil diabetes study group. JAMA. 1999;281(5):421–426.
  • Kloner RA, Brown M, Prisant LM, et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil study group. Am J Hypertens. 2001;14(1):70–73.
  • El-Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. Eur Urol. 2004;46(4):503–509.
  • El-Sakka AI, Anis T, Khadr N, et al. Youseif E sildenafil treatment of erectile dysfunction in the Middle East: an observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting. J Int Med Res (JIMR). 2011;39:558–568.
  • González-Corrochano R, La FJ, Cuevas P, et al. Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. Br J Pharmacol. 2013 May;169(2):449–461.
  • Guagnini F, Ferazzini M, Grasso M, et al. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabeticanimals and human isolated corpora cavernosa. J Transl Med. 2012 Mar 23;10:59.
  • Montorsi F, Padma-Nathan H, Buvat J, et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebocontrolled trial. J Sex Med. 2004;1(2):168–178.
  • Mátyás C, Németh BT, Oláh A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail. 2017 Mar;19(3):326–336.
  • Santi D, Granata AR, Guidi A, et al. Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial. Eur J Endocrinol. 2016 Apr;174(4):513–522.
  • Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280–288.
  • Chen Y, Li XX, Lin HC, et al. The effects of long-term administration of tadalafil on STZ-induced diabetic rats with erectile dysfunction via a local antioxidative mechanism. Asian J Androl. 2012 Jul;14(4):616–620.
  • Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010;32(6):1178–1187.
  • Yilmaz D, Bayatli N, Un O, et al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014 Feb;83(2):508.e7–12.
  • Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. 2012 Sep;87(9):843–852.
  • Gao ZW, Zhu YT, Yu MM, et al. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin. 2015;36:1528–1536.
  • Wang Z, Zhu D, Yang X, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 2013;10:2790–2797.
  • Ahn GJ, Chung HK, Lee CH, et al. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009;11:435–442.
  • Park SH, Park SW, Cha BY, et al. Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. Asian J Androl. 2015 Jan-Feb;17(1):143–148.
  • Cho MC, Paick JS. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. Ther Adv Urol. 2016 Apr;8(2):100–117.
  • Park HJ, Choi HK, Ahn TY, et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. J Sex Med. 2010 Aug;7(8):2842–2850.
  • Hatzichristou D, d’Anzeo G, Porst H, et al. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. BMC Urol. 2015;15:111.
  • Choi WS, Kwon OS, Cho SY, et al. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats. J Sex Med. 2015;12:600–610.
  • Brock G, Ni X, Oelke M, et al. Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med. 2016 May;13(5):860–875.
  • Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16:51–59.
  • Faulkner LD, Dowling AR, Stuart RC, et al. Reduced melanocortin production causes sexual dysfunction in male mice with POMC neuronal insulin and leptin insensitivity. Endocrinology. 2015 Apr;156(4):1372–1385.
  • Lal S, Rios O, Thavundayil JX. Treatment of impotence with trazodone: a case report. J Urol. 1990;143:819–820.
  • Adaikan PG, Ng SC, Chan C, et al. Oral trazodone in the treatment of total secondary impotence in a diabetic patient. Br J Urol. 1991 Aug;68(2):212–213.
  • Tanweer MS, Fatima A, Rahimnajjad MK. Yohimbine can be the new promising therapy for erectile dysfunction in type 2 diabetics. J Pak Med Assoc. 2010 Nov;60(11):980.
  • Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45(2):200–206.
  • El-Sakka AI. What is the current role of intracavernosal injection in management of erectile dysfunction? Int J Impot Res. 2016 May;28(3):88–95.
  • Zhou ZY, Zhong GJ, Cheng SP, et al. Li F Short hairpin rna targeting insulin-like growth factor binding protein-3 restores the bioavailability of insulin-like growth factor-1 in diabetic rats. Int Braz J Urol. 2016 Jan-Feb;42(1):139–145.
  • Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1–7.
  • Wang J, Ai X, Li L, et al. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. 2017 Nov;49(11):2019–2026.
  • El-Sakka AI, Sayed HM, Tayeb KA. Diabetes-associated androgen alteration in patients with erectile dysfunction. Int J Androl. 2008;31:602–608.
  • El-Sakka AI, Sayed HM, Tayeb KA. Androgen pattern in patients with type 2 diabetes associated erectile dysfunction: impact of metabolic control. Urology. 2009;74:552–560.
  • Dhindsa SS, Prabhakar M. Sethi et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5462–5468.
  • Dimitriadis F, Sofikitis N. Effect of testosterone replacement treatment on constitutional and sexual symptoms in type 2 diabetic men: need for rules. Asian J Androl. 2015 Mar-Apr;17(2):217–218.
  • Lasker GF, Pankey EA, Frink TJ, et al. The sGC activator BAY 60–2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol. 2013;304:H1670–9.
  • Estancial CS, Rodrigues RL, De Nucci G, et al. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60–2770 in rabbit corpus cavernosum. BJU Int. 2015;116:657–664.
  • Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755–768.
  • Nunes KP, Teixeira CE, Priviero FB, et al. Webb RC Beneficial effect of the soluble guanylyl cyclase stimulator BAY 41–2272 on impaired penile erection in db/db-/- type II diabetic and obese mice. J Pharmacol Exp Ther. 2015 May;353(2):330–339.
  • Oudot A, Behr-Roussel D, Poirier S, et al. Combination of BAY 60–4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov;60(5):1020–1026.
  • Wen J, Wang B, Du C, et al. A2B adenosine receptor agonist improves erectile function in diabetic rats. Tohoku J Exp Med. 2015 Oct;237(2):141–148.
  • Yousif MH, Makki B, El-Hashim AZ, et al. Chronic treatment with Ang-(1–7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes. J Diabetes Res. 2014;2014:142154.
  • Yin GN, Choi MJ, Kim WJ, et al. Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse. Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2731–40.
  • Jin HR, Kim WJ, Song JS, et al. Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. Diabetes. 2011 Mar;60(3):969–980.
  • Angeloni NL, Bond CW, McVary KT, et al. Sonic hedgehog protein is decreased and penile morphology is altered in prostatectomy and diabetic patients. PLoS One. 2013 Aug 14;8(8):e70985. . eCollection 2013.
  • Angeloni NL, Bond CW, Tang Y, et al. Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers. Biomaterials. 2011 Feb;32(4):1091–1101.
  • Minaz N, Razdan R, Pathak L. Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: in silico, in vitro and in vivo approach. Pharmacol Rep. 2018 Apr;70(2):309–315.
  • Cui K, Tang Z, Li CC, et al. Lipoxin A4 improves erectile dysfunction in rats with type I diabetes by inhibiting oxidative stress and corporal fibrosis. Asian J Androl. 2018 Mar-Apr;20(2):166–172.
  • Safaeinejad F, Bahrami S, Redl H, et al. Inhibition of inflammation, suppression of matrix metalloproteinases, induction of neurogenesis, and antioxidant property make bryostatin-1 a therapeutic choice for multiple sclerosis. Front Pharmacol. 2018 Jun 19;9:625.
  • Cui K, Ruan Y, Wang T, et al. FTY720 supplementation partially improves erectile dysfunction in rats with streptozotocin -induced type 1 diabetes through inhibition of endothelial dysfunction and corporal fibrosis. J Sex Med. 2017 Mar;14(3):323–335.
  • Gong SG, Wang L, Pudasaini B, et al. Transition from ambrisentan to bosentan in pulmonary arterial hypertension: a single-center prospective study. Can Respir J. 2018 Apr;11(2018):9836820.
  • Alkan E, Ugan RA, Basar MM, et al. Role of endothelin receptors and relationship with nitric oxide synthase in impaired erectileresponse in diabetic rats. Andrologia. 2017 Mar;49:2.
  • Soebadi MA, Moris L, Castiglione F, et al. Advances in stem cell research for the treatment of male sexual dysfunctions. Curr Opin Urol. 2016;26:129–139.
  • Levy JA, Marchand M, Iorio L, et al. Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc. 2016;116:e1–5.
  • Yang R, Fang F, Wang J, et al. Adipose-derived stem cells ameliorate erectile dysfunction after cavernous nerve cryoinjury. Andrology. 2015;3:694–701.
  • Yiou R, Hamidou L, Birebent B, et al. Safety of intracavernous bone marrow mononuclear cells for postradical prostatectomy erectile dysfunction: an open doseescalation pilot study. Eur Urol. 2016 Jun;69(6):988–991.
  • Song L, Zhu J, Zhang X, et al. BDNF hypersecreting human umbilical cord blood mesenchymal stem cells promote erectile function in a rat model of cavernous nerve electrocautery injury. Int Urol Nephrol. 2016;48:37–45.
  • Liu T, Peng Y, Jia C, et al. Hepatocyte growth factor-modified adipose tissue-derived stem cells improve erectile function in streptozotocin-induced diabetic rats. Growth Factors. 2015;33(4):282–289.
  • Ryu JK, Kim DH, Song KM, et al. Intracavernous delivery of clonal mesenchymal stem cells rescues erectile function in the streptozotocin-induced diabetic mouse. Andrology. 2016 Jan;4(1):172–184. . Epub 2015 Dec 29.
  • Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010 Jun;8(2):150–160.
  • Shin YS, Zhao C, Zhang LT, et al. Current status and clinical studies of oriental herbs in sexual medicine in Korea. World J Mens Health. 2015;33:62–72.
  • Wang X, Liu C, Xu Y, et al. Combination of mesenchymal stem cell injection with icariin for the treatment of diabetes-associated erectile dysfunction. PLoS One. 2017 Mar 28;12(3):e0174145.
  • Bai GY, Zhou F, Hui Y, et al. Effects of Icariside II on corpus cavernosum and major pelvic ganglion neuropathy in streptozotocin-induced diabetic rats. Int J Mol Sci. 2014 Dec 15;15(12):23294–23306.
  • Zhang J, Li AM, Liu BX, et al. Effect of icarisid II on diabetic rats with erectile dysfunction and its potential mechanism via assessment of AGEs, autophagy, mTOR and the NO-cGMP pathway. Asian J Androl. 2013 Jan;15(1):143–148.
  • Kim KS, Bae WJ, Kim SJ, et al. Improvement of erectile dysfunction by the active pepide from Urechis unicinctus by high temperature/pressure and ultra - wave assisted lysis in streptozotocin induced diabetic rats. Int Braz J Urol. 2016 Jul-Aug;42(4):825–837.
  • Feng XT, Qin CB, Leng J, et al. Yidiyin, a Chinese herbal decoction, improves erectile dysfunction in diabetic patients and rats through the NO-cGMP pathway. Biosci Biotechnol Biochem. 2012;76(2):257–263.
  • Bai Y, An R. Resveratrol and sildenafil synergistically improve diabetes associated erectile dysfunction in streptozotocin-induced diabetic rats. Life Sci. 2015;135:43–48.
  • Yu W, Wan Z, Qiu XF, et al. Resveratrol, an activator of SIRT1, restores erectile function in streptozotocin-induced diabetic rats. Asian J Androl. 2013 Sep;15(5):646–651.
  • Sawant SD, Lakshma Reddy G, Dar MI, et al. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. Bioorg Med Chem. 2015;23:2121–2128.
  • Nishimatsu H, Suzuki E, Saito Y, et al. Neuromedin B restores erectile function by protecting the cavernous body and the nitrergic nerves from injury in a diabetic rat model. PLoS One. 2015 Jul 24;10(7):e0133874. eCollection 2015.
  • Han G, Tar M, Kuppam D, et al. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med. 2010;7:224–233.
  • Lin H, Dhanani N, Tseng H, et al. Nanoparticle improved stem cell therapy for erectile dysfunction in a rat model of cavernous nerve injury. J Urol. 2016;195:788–795.
  • Park J, Kwon OS, Cho SY, et al. Chronic administration of atorvastatin could partially ameliorate erectile function in streptozotocin-induced diabetic rats. PLoS One. 2017 Feb 28;12(2):e0172751. eCollection 2017.
  • Cai X, Tian Y, Wu T, et al. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl. 2014 May-Jun;16(3):461–466.
  • Giagulli VA, Carbone MD, Ramunni MI, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015 Nov;3(6):1094–1103.
  • Wang L, Xu Y, Li H, et al. Antioxidant icariside II combined with insulin restores erectile function in streptozotocin-induced type 1 diabetic rats. J Cell Mol Med. 2015 May;19(5):960–969.
  • Zhang X, Kanika ND, Melman A, et al. Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E32–42.
  • Patel JP, Lee EH, Mena-Hurtado CI. Walker CN evaluation and management of erectile dysfunction in the hypertensive patient. Curr Cardiol Rep. 2017 Aug 24;19(9):89.
  • Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997 Jan;29(1 Pt 1):8–14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.